Skip to content
Homepage
Author:
Skyhawk Therapeutics
Posted Date:
June 30, 2026
Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
Skyhawk Therapeutics
June 30, 2026
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
Skyhawk Therapeutics
June 1, 2026
/C O R R E C T I O N — Skyhawk Therapeutics/
Skyhawk Therapeutics
May 22, 2026
Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule
Skyhawk Therapeutics
May 22, 2026
Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society’s 2026 Medal of Honor
Skyhawk Therapeutics
March 30, 2026
Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington’s Disease
Skyhawk Therapeutics
March 10, 2026
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
Skyhawk Therapeutics
January 28, 2026
